|
|
|
 |
|
|
 |
Thursday, April 25th, 2013
12:40pm (EST)
The bulls are pushing all-time highs ahead of tomorrow’s GDP (Gross Domestic Product) report and all signs are pointing to a break out of the current trading range to new highs or a pullback and a test back down to the bottom of the trading range.
Amazon.com (AMZN, $272.71, up $3.93) is scheduled to report their quarterly numbers after the close tonight and Wall Street is looking for earnings of $9 cents a share on revenue of $16.2 billion. The stock trades erratically after they confess to Wall Street as shares have traded up on “bad news” and down on “good news” in years past.
The company has plans to introduce a set top box to better manage its online streaming content and to get more users to shop their site from their TV. There isn’t a lot of money to be made on the boxes themselves but gaining a potential customer to browse their site and buy things is a cheap way of attracting them.
One company that we have been following for years and is often traded in our Daily is Akamai Technologies (AKAM, $43.00, up $6.91) and is up 20% today. Shares had been struggling at $36 with support/ resistance and we knew this would be a big quarter for them. If the growth didn’t return shares would probably test $30 but if they came in with better-than-expected numbers we knew there was a chance shares could fly past $40.
The company reported a profit of $0.51 a share on revenue of $368 million versus expectations for $0.46 a share on revenue of $357 million. Although we sat on the sidelines, the May 40 calls (AKAM130518C00040000, $3.33, up $2.55) are zooming on the news as they are up 327% on the earnings beat.
We have continued to say Akamai is a takeover target and we have said Apple (AAPL, $409.76, up $4.30) should buy the company. Shares have hit a 52-week high of $43.42 but have folded like a cheap lawn chair every time they have tried to hold $40. Maybe this go round will be different.
Another stock getting a nice pop is a small-cap company from our Weekly Wrap. We have been pounding the table on this incredible growth story for over a year now and we originally profiled the stock at $4.50. Shares traded down to $3 earlier this year and we said support would hold and that you should back the truck up. We said once they cleared $3.80 and then $4 they would quickly shoot past $5. Today shares are soaring past $7 and have traded up to $7.40.
Our Weekly Wrap is 12-1 for 2013 and 56-3 overall since we started the publication and we have a number of other current trades that are doing well. The newsletter doesn’t get the fame-and-glory that the Daily does because investors are enamored with triple-digit option trades and often ignore they safety of covered call trading or speculative investments and double-digit returns.
Most of our Daily subscribers are yearly members to the Weekly Wrap and if you are not a current subscriber to the publication, we urge you to take advantage of this discounted offer to join us for 3 months at an incredible low rate. We have made it a reasonable price so you can get in on this s mall-cap stock that is headed to double-digits and we also have a few other gems that could made moves of 50% or more.
Use this coupon code below and associate it with the 3-month Weekly Wrap and you can join us for a over a 50% savings! The cost is just $129 and is normally priced at $261.
Coupon code:
6FBD9B74
Please click here to go to the Subscription Link
Associate with:
Weekly Wrap – 3 Month Subscription Only $261 for 3 months
Weekly newsletter – Stock market review and analysis for upcoming week.
Once you signup you will have instant access to our Weekly Wrap by logging into the Weekly Wrap premium section located on our website.
As far as the market, the Dow is up 70 points to 14,746 while the S&P 500 is higher by 10 points to 1,588. The Nasdaq is advancing 27 points to 3,296 and has kissed 3,300.
We have a NEW TRADE for the Daily today so we have to roll. Subscribers, check the Members Area for the updates as we have other trades in play. We will be back in the AM with a full report.
Posted in BioTech, Covered Calls, Earnings, Economic News, Market Analysis, Market Commentary | Comments Off
Friday, December 7th, 2012
12:05pm (EST)
We love Christmas time as it is our favorite holiday of the year. It is nice to receive cards, letters, and gifts but it is more about caring. Our subscribers mean a lot to us and every year we offer a huge discount on yearly memberships because we want you to learn how the market works and we want you to find your own trades. More importantly, we want you to make money. There is no bigger thrill once you learn to trade options and find your own trade that returns you 500% in a matter of days or hours.
We are a high risk/ high reward option investment Daily newsletter and we also offer “safer” option and stock trades through our Weekly Wrap newsletter. The Daily newsletter targets triple-digit returns for every trade and offers 2-3 trades a week, depending on market conditions. We have nearly 200 trades on the books this year and our Track Record is 122-54 for nearly a 70% win rate. We have recommended over 30 triple-digit winners with gains up to 400%-500% and most trade recommendations range from 50%-80% returns.
For our Weekly Wrap, we are 26-0 on trade recommendations. We were 16-0 in 2011 and we are 42-0 since inception. Overall for 2012, our Track Record is 147-54 which is a 73% success rate. This is by far, one of the best, if not the best, option trading services out there. We have not had a losing year since we started the newsletter in 2008.
The cost for a 1-year membership is $924 for the Daily. This is $77/ month and much less than the $97 or $129 monthly memberships. The Weekly Wrap is also $924 for a 1-year deal.
We will be offering them BOTH for $924. This is a 50% savings.
We also offer an option trading course, How to Trade Options on Momentum Stocks, that is valued at $895. The course comes with bi-monthly videos and currently has dozens of videos on trade setups, how to find trades, and how to read charts. The course is also shipped to you at no charge and you can read more here.
We are also doing two more special incentives. One is we are offering an extra 20% discount through this weekend only that will lower the price to $740/ or around $60 a month for both publications.
We do this because we will be printing the new, updated option trading manual with more charts and tips, and we need to know how many we need to print and to keep our costs (and yours) as low as possible. After this weekend, there will not be a 20% discount but you can still get both the Daily and Weekly Wrap for $924.
The iPad offer is this. If you signup this weekend for the 1-year deal, you will be eligible to enter an educated guess on where the Dow will be on the last trading day of the year at the close on December 31, 2012.
We will take all entries by Sunday night by midnight (EST) and we will confirm them with each subscriber. The one who comes the closest on the Dow, over or under, will win a brand new iPad.
Your prediction must list the Dow’s closing price with two decimal points. In other words, if you believe the Dow will end at 13,600 – you will need to use 13,600.00.
The coupon code for the 20% discount and the special deal will end Sunday night. You will need to click on the 1-year Daily subscription link and enter the code to get the discount. You will need to email our support team no later than 11:59pm (EST), Sunday, December 9, 2012. We will list the high and low predictions on Tuesday morning.
You can also call us if you have questions.
The special offer will run through December but in order to get the EXTRA 20% discount and the chance to win a beautiful, brand spanking new iPad, you must signup this weekend!
We cannot break these rules so please do not write and ask us on Monday if it is too late to get in. It would not be fair to other subscribers.
The next video for our option course will be out soon and we will be covering a host of topics so make sure you get on board. This is by far, the best deal we offer and it only comes along once a year.
Here is the coupon and please be sure to click the 1-year Daily membership.
5A6155273A
Click here to go to our subscription page.
As we head to press, the Dow is up 31 points to 13,105 while the S&P 500 is lower by 2 points to 1,412. The Nasdaq is off 17 points to 2,972.
Have a GREAT weekend everyone and we will be beack Monday Morning!
Posted in Apple, BioTech, China, Commodities, Company Commentary, Covered Calls, Earnings, Economic News, Entertainment Stocks, Hot Stocks, IPOs, Market Analysis, Market Commentary, Mergers and Acquisitions, Money Management, Oil, Option Trades, Politics | Comments Off
Tuesday, August 7th, 2012
1:35pm (EST)
Over the years, we have covered quite a few explosive biotech stocks that have made incredible returns for our subscribers but sometimes we can overlook the 800-pound gorillas in the room.
We have been following shares of Pfizer (PFE, $23.84, down $0.42) for years but we rarely, if ever, play options on the stock as a directional call or put play. Shares don’t quite move as much as they did in the late 90’s which saw the stock split 4 times and growth was abundant. Nowadays, there is risk associated in owning the stock as some of Pfizer’s drugs come off patient and face competition risks.
There are also risks with developing new drugs as research and development, clinical trials, and marketing can get expensive. However, getting a multi-billion dollar blockbuster drug approved and to market can be lucrative for years to come.
Pfizer had high hopes for its Alzheimer’s drug, Bapineuzumab, which it was in development with Johnson & Johnson (JNJ, $68.37, down $0.48) and Elan (ELN, $10.87, down $0.38) but halted plans to develop the drug after another trial failure.
Bapineuzumab was in the second stage of a final 4-stage trial but failed to improve the symptoms of dementia. In late July, the drug also failed a late-stage trial.
Alzheimer’s is a hard disease to crack and there hasn’t been much advancement in finding a cure. Pfizer decided to pull the plug and go back to the drawing board but they will be looking to partner with another biotech company that may have a new cure for Alzheimer’s in their pipeline.
Shares of Pfizer looked like a steal under $20 but we waffled on the chance to buy it in the high teens and add it to our Weekly Wrap covered call portfolio. We mentioned a few years ago Pfizer should’ve have taken a hard look at Vivus (VVUS, $23.24, up $2.02) or Arena Pharmaceuticals (ARNA, $7.41, up $0.20) as a possible play in the obesity market but they ignored us.
We have done well with Vivus and Arena this year by playing both the stock and options. Vivus has returned our subscribers numerous double-digit gains over the past couple of years. In 2011, we recommended covered calls 3 times that made our subscribers 18%, 17% and 14% as shares traded below $10 for much of the year. In January, we went back to the well and suggested another Vivus covered call trade that made our subscribers 38% by March.
We also started recommending Arena back in February when shares were just above $2. We used the juicy premiums in the calls options to lower our risk to $1.88 and in July our Weekly Wrap subscribers closed a trade for a 117% return. In March, we made 12% on a quick Arena call option trade but rolled the position over in late April and early May to get repositioned. Those 2 call options trades made our subscribers 464% and 54%, respectively.
Although we don’t own Pfizer, we did reload on Vivus again in July and we are hoping to make a double-digit profit by next Friday with the trade. As far as Pfizer, we would love to see shares fall back to $20 but support is strong at $22 and we doubt shares fall 10% on this news. They could over the next few weeks and we are watching Pfizer closely as a possible covered call trade, but for now, we are happy holding Vivus.
As far as the market, the bulls have pierced resistance and have cleared our next wave of price targets. We will have to see how the indexes end at the close but we are still waiting to see if there will be a breakout. In the meantime, we have a couple of trades in our Weekly Wrap that are allowing us to enjoy the upside and the new trades for our Daily have September expiration dates so we have plenty of time to wait for a pullback while the bulls continue running.
When the market is in a trading range, it is best to have both long and short positions which should offset some of the volatility we have been seeing. Although we are itchy to trade, we are trying to remain disciplined to avoid the urge of adding call options or buying more puts until we get a few more signals on where this market is headed over the next month or two and not just today.
As we head to press, the Dow is up 97 points to 13,214 while the S&P is higher by 12 points to 1,406. The Nasdaq is popping 35 points and is at 3,024. Subscribers, check the Members Area for the updates.
Tags: ARNA, Bapineuzumab drug trials, biotech options, biotech stock, VVUS
Posted in BioTech, Hot Stocks | Comments Off
Wednesday, June 27th, 2012
2:15pm (EST)
We always say plan your trades and trade your plan.
Arena Pharmaceuticals (ARNA, $11.87, up $3.02) has opened for trading and we are seeing strong gains on our options. We recommended the July 3 calls (ARNA120723C00003000, $9.00, up $3.00) at $1 back in late April and after locking-in profits along the way, we are ringing the register on a trade that is up 464%.
We said shares should open near $12 but they have traded up to $13.50 so our targets have been hit.
We also have a NEW TRADE we are adding as we see some dark storm clouds on the horizon.
Subscribers, check the Members Area for the updates and we will be back in the morning with the full story.
Tags: ARNA
Posted in BioTech, Trade Update | Comments Off
Wednesday, June 27th, 2012
1:00pm (EST)
The bulls are making another push higher and have cracked the first layer of resistance as we head into the second half of trading. We mentioned this morning inside our Members Area that the current choppy action could continue for a few weeks if the market followed last year’s pattern but things are different this year.
Of course, betting on history does not mean the market will follow typical trading patterns but we have been in somewhat of a trading range all year as the market is trading near its February lows. This week’s news and upcoming earnings should provide enough volatility that a trend will emerge over the next week or two.
The European Union summit, jobless claims, earnings warnings, and upcoming earnings which start the week after next, could influence direction that could sway the Dow 1,000 points over the next 3 weeks. If you think June volatility has been whacky, wait until July and August roll around.
Arena Pharmaceuticals (ARNA, $8.73, down $0.12) was still trading as we were getting ready to go to press but shares were halted at 12:40pm. We have been following this story for years and today will be a big payday for our subscribers. We recommended backing the truck up when shares were at $2 in February and we have already locked-in triple-digit profits as shares have zoomed in recent weeks.
Much or our risk has already been taken off the table so the news won’t affect us either way as we have closed ¾ of the trade for our Daily. An approval for the company’s obesity drug, Lorcaserin, should push shares back above double-digits while a delay or rejection would probably hammer shares below $5.
If the stocks fall to $5 our call options should still yield a profit of at least 339%. If the stock moves past $10-$12, we should have a profit of nearly 500%. For our Weekly Wrap, our gains are capped at 117% as long as the stock $3 holds. We recommended buying Arena when shares were at $1.88 on February 2nd and for every 100 shares you purchased to sell the July 3 calls for 50 cents. This lowered the cost basis to $1.33.
Either way, we can’t complain but we would like to see the drug come to market so we can maximize our gains. We have taken steps to control risk so all we have to do is sit back and wait for the news.
We have also closed 2 more winning trades today that retuned our subscribers 43% and 33% in less than a week. Although the market is whipsawing us on a few of our positions, we have been prepared for the choppy action as we wait for a clear trend to develop.
As far as the market, the Dow is up 90 points to 12,625 while the S&P 500 is higher by 12 points to 1,332. The Nasdaq is getting a nice pop today and is showing a gain of 24 points and was last seen at 2,878.
We were going to send out a News Flash once we got word on Arena and we just did as we were typing our last sentence. Their obesity drug won approval!
As usual, we have a lot more action to cover inside our Members Area so let’s get to it!
Tags: Arena call option trades, ARNA, ARNA call options, FDA apporval for Arena, Lorcaserin obesity drug
Posted in BioTech, Hot Stocks | Comments Off
|
|
|  | | | |
Get RSS Feed
SPECIAL OFFER!/ S&P Testing All-Time Highs/ Amazon (AMZN) After the Bell/ New Trade!
Thursday, April 25th, 2013
12:40pm (EST)
The bulls are pushing all-time highs ahead of tomorrow’s GDP (Gross Domestic Product) report and all signs are pointing to a break out of the current trading range to new highs or a pullback and a test back down to the bottom of the trading range.
Amazon.com (AMZN, $272.71, up $3.93) is scheduled to report their quarterly numbers after the close tonight and Wall Street is looking for earnings of $9 cents a share on revenue of $16.2 billion. The stock trades erratically after they confess to Wall Street as shares have traded up on “bad news” and down on “good news” in years past.
The company has plans to introduce a set top box to better manage its online streaming content and to get more users to shop their site from their TV. There isn’t a lot of money to be made on the boxes themselves but gaining a potential customer to browse their site and buy things is a cheap way of attracting them.
One company that we have been following for years and is often traded in our Daily is Akamai Technologies (AKAM, $43.00, up $6.91) and is up 20% today. Shares had been struggling at $36 with support/ resistance and we knew this would be a big quarter for them. If the growth didn’t return shares would probably test $30 but if they came in with better-than-expected numbers we knew there was a chance shares could fly past $40.
The company reported a profit of $0.51 a share on revenue of $368 million versus expectations for $0.46 a share on revenue of $357 million. Although we sat on the sidelines, the May 40 calls (AKAM130518C00040000, $3.33, up $2.55) are zooming on the news as they are up 327% on the earnings beat.
We have continued to say Akamai is a takeover target and we have said Apple (AAPL, $409.76, up $4.30) should buy the company. Shares have hit a 52-week high of $43.42 but have folded like a cheap lawn chair every time they have tried to hold $40. Maybe this go round will be different.
Another stock getting a nice pop is a small-cap company from our Weekly Wrap. We have been pounding the table on this incredible growth story for over a year now and we originally profiled the stock at $4.50. Shares traded down to $3 earlier this year and we said support would hold and that you should back the truck up. We said once they cleared $3.80 and then $4 they would quickly shoot past $5. Today shares are soaring past $7 and have traded up to $7.40.
Our Weekly Wrap is 12-1 for 2013 and 56-3 overall since we started the publication and we have a number of other current trades that are doing well. The newsletter doesn’t get the fame-and-glory that the Daily does because investors are enamored with triple-digit option trades and often ignore they safety of covered call trading or speculative investments and double-digit returns.
Most of our Daily subscribers are yearly members to the Weekly Wrap and if you are not a current subscriber to the publication, we urge you to take advantage of this discounted offer to join us for 3 months at an incredible low rate. We have made it a reasonable price so you can get in on this s mall-cap stock that is headed to double-digits and we also have a few other gems that could made moves of 50% or more.
Use this coupon code below and associate it with the 3-month Weekly Wrap and you can join us for a over a 50% savings! The cost is just $129 and is normally priced at $261.
Coupon code:
6FBD9B74
Please click here to go to the Subscription Link
Associate with:
Weekly Wrap – 3 Month Subscription Only $261 for 3 months
Weekly newsletter – Stock market review and analysis for upcoming week.
Once you signup you will have instant access to our Weekly Wrap by logging into the Weekly Wrap premium section located on our website.
As far as the market, the Dow is up 70 points to 14,746 while the S&P 500 is higher by 10 points to 1,588. The Nasdaq is advancing 27 points to 3,296 and has kissed 3,300.
We have a NEW TRADE for the Daily today so we have to roll. Subscribers, check the Members Area for the updates as we have other trades in play. We will be back in the AM with a full report.
Posted in BioTech, Covered Calls, Earnings, Economic News, Market Analysis, Market Commentary | Comments Off